Korea-Seoul Life Science Fund

Korea-Seoul Life Science Fund is a venture capital firm established in 2011 and located in Cambridge, Massachusetts. The firm specializes in investing in life sciences companies, targeting sectors such as biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare. With a focus on opportunities in both Asia and the United States, Korea-Seoul Life Science Fund aims to support innovative companies that contribute to advancements in health and medicine.

Jonathan J. Fleming

General Partner

2 past transactions

EuBiologics

Series B in 2014
EuBiologics Co., Ltd. is a biopharmaceutical company based in Seoul, South Korea, focused on developing and supplying vaccines to address epidemics and antibiotic resistance. The company offers innovative products such as Euvchol, an oral cholera vaccine, and CRM197, a diphtheria toxin mutant vaccine. In addition to its vaccine development, EuBiologics provides customized services for the production of biopharmaceuticals derived from mammalian and microbial cells. These services encompass cell line development, GMP production, validation, and regulatory support. The company also specializes in the manufacture of recombinant biological products and antibody therapeutics. Furthermore, EuBiologics offers process development, formulation, analytical method development, and contract testing services, including lot release and stability testing. Founded in 2010, EuBiologics is dedicated to advancing healthcare solutions through its comprehensive biopharmaceutical capabilities.

CG Pharmaceuticals

Series A in 2012
CG Pharmaceuticals, also known as CrystalGenomics, Inc., is a biopharmaceutical company based in Seongnam, South Korea, with a presence in Emeryville, California. The company specializes in drug discovery and development using structural chemoproteomics. Its lead candidate, CG100649, is a tissue-specific anti-inflammatory agent that has demonstrated safety in cardiovascular, gastrointestinal, and renal contexts and has completed Phase IIa clinical trials. Additionally, CG Pharmaceuticals is developing CG200745, a histone deacetylase inhibitor targeting cancer, currently in Phase I trials, and CG400549, an antibiotic aimed at treating infections from methicillin-resistant and vancomycin-resistant strains of Staphylococcus aureus, also in Phase I trials. The company offers services related to protein cloning, expression, purification, characterization, and assay development. CG Pharmaceuticals collaborates with several industry leaders, including AstraZeneca, Daiichi-Sankyo, and Hanmi Pharmaceuticals, fostering innovation in drug development since its founding in 2000.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.